GIST study

Study name:

A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS

Eligibility:

Patients who have locally advanced, metastatic, and/or unresectable GIST, and have received prior therapy with imatinib.

Treatment 1:

CGT9486 plus Sunitinib

Treatment 2:

Sunitinib